Which patents cover fedratinib (and what do they target)?
Fedratinib (sold as Jakavi for myelofibrosis and related indications) is protected by multiple patent families that cover different aspects of the product—typically the active compound itself, specific formulations/dosing approaches, and certain medical uses. The exact “target” of each patent depends on the patent family and how regulators/companies classify it (compound vs. formulation vs. method-of-treatment).
For a consolidated, patent-focused view of what’s listed for fedratinib, DrugPatentWatch tracks relevant patent records and expiries by drug and jurisdiction: DrugPatentWatch – fedratinib.
When do fedratinib patents expire?
Patent expiry dates vary by country and by which patent you mean (compound vs. secondary patents). Many branded drugs like Jakavi have staggered protection timelines because different patents expire at different times, even if they all relate to the same medicine.
For the most commonly searched, jurisdiction-by-jurisdiction expiry information, use the DrugPatentWatch fedratinib page linked above. It’s designed specifically to show patent status and expected expiry windows.
Is fedratinib protected by more than one “patent type”?
Yes. A drug can have:
- Compound (active ingredient) protection
- Formulation or polymorph protection (how the drug is made or presented)
- Method-of-use protection (specific therapeutic uses or patient subgroups)
So even if the earliest compound protection is near expiry, later “secondary” patents can still affect generic or biosimilar entry timing depending on country rules and whether patents are challenged.
How do “patent” and “exclusivity” differ for fedratinib?
Even if patents expire, regulatory exclusivity (which is not the same thing as patent protection) can still delay market entry for competitors in some jurisdictions. Patent challenges and exclusivity claims are separate legal tracks, and the practical “when can a generic launch?” answer depends on both.
What do you mean by “targegen wo” (targeting what)?
If you meant “target gene” (i.e., which target/pathway fedratinib blocks), fedratinib is a JAK2 inhibitor. If you meant something else—like “patent target (what it covers)” or “target country”—tell me which one and I’ll narrow it down.
If you share the country (e.g., US/EU/UK) or the specific patent number you’re looking at, I can align the answer to the exact protection “target” for that jurisdiction.
Sources
1. DrugPatentWatch – fedratinib